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The epidemic due to severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2) infection has been spreading 
globally, raising increasing concerns. In this scenario, deci-
sions on preventive, symptomatic and potentially life-saving 
treatments both in the general population and in patients 
with novel coronavirus disease 2019 (COVID-19) must be 
based on sound scientific evidence.
Controversial hypotheses about the possible detrimental/
protective effects of antihypertensive drugs acting on the 
renin–angiotensin–aldosterone system (RAAS) in patients 
with COVID-19 have been postulated in several editorials 
and letters [1–4].
Through the regulation of vascular peripheral resistance 
and, potentially, of blood volume, the RAAS plays a crucial 
role in the etiology of hypertension. Moreover, this system 
promotes atherogenic processes by increasing oxidative 
stress, stimulating vascular muscle and monocyte prolif-
eration. Based on their biological target, drugs inhibiting 
the RAAS may be distinguished as angiotensin-converting 
enzyme inhibitors (ACEIs), angiotensin II receptor blockers 
(ARBs) and direct renin inhibitors (DRIs). ACEIs enact their 
blood pressure-lowering effects by blocking the peptidyl-
dipeptidase that hydrolyzes angiotensin I (A-I) to angioten-
sin II (A-II). In addition, it inactivates bradykinin, a vasodi-
lating peptide promoting the release of nitrogen monoxide 
and prostacyclin. ARBs have no effect on bradykinin metab-
olism and block the effects of A-II more selectively than 
ACEIs. In detail, ARBs determine their antihypertensive 
effect by preventing the binding of A-II to the A-II receptor 
type 1  (AT1). Finally, DRIs exert blood pressure-lowering 
effects by decreasing plasma renin activity and inhibiting the 
conversion of angiotensinogen to A-I [5].
In vitro studies demonstrated that ACEIs and ARBs can 
significantly increase the expression and activity of angio-
tensin-conversion enzyme 2 (ACE2), highly expressed in 
the heart and lungs [6]. Coincidentally, ACE2 is the recep-
tor-binding site for the spike protein of SARS-CoV-2 at the 
target cell [7]. Hence, Fang et al. [4] recently hypothesized 
in The Lancet Respiratory Medicine that patients with car-
diac diseases, hypertension, or diabetes mellitus treated with 
ACE2-increasing drugs might be at higher risk for severe 
SARS-CoV-2 infection. Accordingly, the authors suggested 
that calcium channel blockers (CCBs) may be a more suit-
able alternative antihypertensive treatment than ARBs/
ACEIs because of their lack of increased ACE2 expression 
or activity.
On the other hand, recently published commentaries 
outlined the mechanisms by which RAAS inhibitors may 
be beneficial in patients with COVID-19 and discussed the 
unclear effects of these drugs on ACE2 levels and activity 
in humans, recommending against the suspension or with-
drawal of RAAS blockers [8, 9]. We present here our contri-
bution to the scientific debate, highlighting the importance 
of continuing ACEI/ARB treatments and reporting several 
arguments against switching from ACEIs or ARBs to other 
antihypertensive drugs and specifically to CCBs.
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First, to date, there is no sound evidence from clinical 
studies that replacing ACEIs/ARBs with other antihyper-
tensive drugs, including CCBs, is associated with benefi-
cial effects on either the prevention of COVID-19 or the 
prognosis for infected patients. The scant available data 
are mostly derived from in vitro studies. For this reason, 
in Nature Cardiology, Zheng et al. [2] reported, “Whether 
patients with COVID-19 and hypertension who are taking 
[an] ACE inhibitor/ARB should switch to another antihy-
pertensive drug remains controversial, and further evidence 
is required” [2].
Second, other studies carried out in SARS-CoV and prob-
ably generalizable to SARS-CoV-2 suggested, paradoxically, 
a protective effect of ARBs against COVID-19 [1]. The 
interaction of the coronavirus spike protein with ACE2, its 
cellular-binding site, leads to ACE2 downregulation. In turn, 
this results in excessive production of angiotensin by ACE, 
whereas less ACE2 is capable of converting it to angioten-
sin (1-7), an heptapeptide with vasodilator activity [1, 10]. 
It has been suggested that exaggerated stimulation of  AT1 
by A-II determines increased pulmonary vascular perme-
ability, thereby mediating increased lung pathology when 
the expression of ACE2 is decreased [11, 12]. Thus, higher 
ACE2 expression following chronic treatment with ARBs 
may protect patients infected with SARS-CoV-2 against 
acute lung injury rather than increasing the risk of develop-
ing COVID-19.
Third, switching among different antihypertensive drugs 
in older patients with relevant comorbidities may put this 
very frail population at risk of developing adverse cardiovas-
cular events such as uncontrolled hypertension/symptomatic 
hypotension or even deterioration of other chronic diseases. 
Moreover, considering the proven effects of ACEIs and 
ARBs in reducing mortality in cardiovascular diseases, the 
discontinuation of these therapies could increase the occur-
rence of negative outcomes in patients affected by cardio-
vascular diseases and COVID-19 [13].
Fourth, ACEIs and ARBs are currently approved (with 
differences across various compounds) for the treatment of 
hypertension, heart failure and diabetic nephropathy and 
for secondary prevention after acute myocardial infarction, 
whereas CCBs and other antihypertensive drugs are not 
approved for all the same indications.
Finally, none of the drug regulatory agencies worldwide 
recommend switching from ACEIs/ARBs to other antihyper-
tensive drugs or vice versa during the COVID-19 outbreak. 
Instead, on 17 March 2020, the Italian Drug Agency issued 
a warning against any change of antihypertensive therapies 
in patients with well-controlled hypertension, irrespective 
of the agents being used, because of the lack of clinical 
data [14]. Ten days later, the European Medicines Agency 
advised that, since there is no clinical evidence that these 
drugs can worsen SARS-CoV-2 infections, it is important 
that patients do not discontinue their treatment with ACEIs 
or ARBs and there is no need to switch to other medicines 
[15]. These recommendations are in line with the position 
statements of national/international scientific societies 
(e.g., European Society of Cardiology [16], Italian Society 
of Pharmacology [17], Heart Failure Society of America, 
American College of Cardiology and American Heart Asso-
ciation [18], International Society of Hypertension [19], 
European Society of Hypertension [20]) that recommend 
continuing RAAS inhibitor therapy for patients who are cur-
rently prescribed such agents for indications for which it is 
known that these agents are safe and effective, such as acute 
and chronic heart failure [21], acute myocardial infarction 
[22] and hypertension [23].
Regarding the postulated protective effect, ACEIs/ARBs 
should never be used in healthy people or patients who are 
not affected by diseases that are not approved indications as 
reported in the summary of product characteristics.
No specific information has been described for DRIs. 
Nevertheless, all the recommendations reported above can 
be extended to this class of RAAS inhibitors.
In a scenario in which experimental clinical studies can-
not rapidly shed light on the association between COVID-19 
and ACEI/ARB use, real-world studies based on dedicated 
COVID-19 patient registries, whenever available, or claims 
databases from countries with a high incidence of SARS-
CoV-2 infection are urgently needed.
In the absence of clinical evidence supporting any change 
in patients treated with ACEIs/ARBs, clinicians should still 
follow the old principle “primum non nocere.”
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